Claims
- 1. A compound of the Formula I:
- 2. A compound of the Formula II:
- 3. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt according to claim 2, wherein:
R1 is substituted or unsubstituted aryl or heteroaryl, or R6—CO or R6—CS where R6 is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl, aryl, heteroaryl, alkoxy, or N—R7R8 where R7R8 are each independently hydrogen or substituted or unsubstituted alkyl, aryl, or heteroaryl; R2 is substituted or unsubstituted aryl or heteroaryl; X and Y are each independently C or N; and Z is S or O.
- 4. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt according to claim 3, wherein:
R1 and R2 are each independently a substituted aryl; X is C; Y is C or N; and Z is S or O.
- 5. A compound of the Formula III:
- 6. A compound of the Formula IV:
- 7. A compound, pharmaceutically acceptable prodrug, pharmaceutically acceptable metabolite, or pharmaceutically acceptable salt according to claim 6, wherein: R1 is substituted or unsubstituted aryl or heteroaryl, or R6—CO where R6 is N—R7R8 where R7R8 are each independently hydrogen, alkyl, aryl, or heteroaryl; R3 is substituted or unsubstituted alkyl, aryl, heteroaryl, or alkoxy; R4(a) and R4(b) are each independently hydrogen, lower alkyl, or halo; Y is C or N; and Z is S or O.
- 8. A compound, pharmaceutically acceptable prodrug, pharmaceutically acceptable metabolite, or pharmaceutically acceptable salt according to claim 7, wherein: R1 is substituted or unsubstituted aryl or heteroaryl, or R6—CO where R6is N—R7R8 where R7R8 are each independently hydrogen, alkyl, aryl, or heteroaryl; R3 is substituted or unsubstituted aryl, heteroaryl, or alkoxy; R4(a) is chloro, fluoro, or methyl; R4(b) is fluoro; Y is N; and Z is O.
- 9. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt of claim 1; and (b) a pharmaceutically acceptable carrier, diluent, vehicle or excipient therefor.
- 10. A method of treating a mammalian disease condition mediated by protein kinase activity, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1.
- 11. A method according to claim 10, wherein the mammalian disease condition is associated with tumor growth, cell proliferation, or angiogenesis.
- 12. A method of modulating the activity of a protein kinase receptor, comprising contacting the kinase receptor with an effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1.
- 13. A method according to claim 12, wherein the protein kinase receptor is a VEGF receptor.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/137,810, filed Jun. 4, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60137810 |
Jun 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09587530 |
Jun 2000 |
US |
Child |
09783584 |
Feb 2001 |
US |